Fever Power
Business Today India|April 16, 2023
The market for anti-flu drug Oseltamivir in India has grown over 3x in the past three years, with Cipla, Hetero and Macleods being the biggest gainers
NEETU CHANDRA SHARMA
Fever Power

IT’S THAT TIME of the year again when the spread of influenza reaches fever pitch. And with the flu season on us, can medication to treat it be far behind? Data from Pharmarack, an integrated B2B healthcare platform, reveals that sales of antiviral drug Oseltamivir, commonly known as Tamiflu, has seen healthy growth in the past three months. In December 2022, at least 227,000 units of the drug were sold, which shot up to 294,000 units in January 2023 and 395,000 units in February 2023, with a value of ₹9.7 crore, ₹12.8 crore and ₹29 crore, respectively.

The uptick in sales can be linked to the rising flu cases in the country. According to the data available on the Integrated Disease Surveillance Programme-Integrated Health Information Platform (IDSP-IHIP) under the Ministry of Health and Family Welfare, a total of 3,038 laboratory-confirmed cases of various subtypes of influenza, including H1N1 and H3N2, had been reported till March 9, 2023, by the states.

この記事は Business Today India の April 16, 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Business Today India の April 16, 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BUSINESS TODAY INDIAのその他の記事すべて表示
BUILDING TOMORROW'S CARE TODAY
Business Today India

BUILDING TOMORROW'S CARE TODAY

The Indian pharma industry is at a juncture where digital transformation is sweeping the healthcare landscape

time-read
3 分  |
January 19, 2025
BIG SHOTS
Business Today India

BIG SHOTS

GIVEN THAT MORE THAN 40% OF INDIAN ADULTS ARE STRUGGLING WITH OBESITY AND DIABETES, AFFORDABLE WEIGHT-LOSS DRUGS ARE EXPECTED TO SIGNIFICANTLY DISRUPT THE PHARMACEUTICAL LANDSCAPE IN THE COUNTRY THIS YEAR. AND, THE WEIGHT MANAGEMENT MARKET COULD REACH ₹3.99 LAKH CRORE BY 2032, GROWING AT A CAGR OF MORE THAN 9%

time-read
10+ 分  |
January 19, 2025
THE END OF AMERICAN FINANCIAL EXCEPTIONALISM
Business Today India

THE END OF AMERICAN FINANCIAL EXCEPTIONALISM

As the dollar cycle reverses and Asia's rise continues, Indian growth will accelerate

time-read
4 分  |
January 19, 2025
HOW TO ADAPT TO EXTREME HEAT
Business Today India

HOW TO ADAPT TO EXTREME HEAT

India is vulnerable to extreme heat and yet unprepared. But various initiatives provide a glimpse of what is possible when collaboration and ingenuity come together

time-read
7 分  |
January 19, 2025
THE WORLD IN 2030
Business Today India

THE WORLD IN 2030

The policy implications are that India would have to maintain a strong link to a re-industrialising US but find a way to use Chinese capital and inputs

time-read
5 分  |
January 19, 2025
A PEEK INTO THE FUTURE
Business Today India

A PEEK INTO THE FUTURE

INDIA IN 2025 AND BEYOND: TRENDS TO WATCH OUT FOR

time-read
1 min  |
January 19, 2025
"STEERING SBI INTO THE FUTURE"
Business Today India

"STEERING SBI INTO THE FUTURE"

C.S. Setty, Chairman of the State Bank of India, talks about his plans for the bank, the strategy for the future, and technology, among other things

time-read
9 分  |
January 19, 2025
"Outlook for India is very positive"
Business Today India

"Outlook for India is very positive"

Paul Uren, Head of Investment Banking (Asia-Pacific), J. P. Morgan, on M&A activity, the environment of investment banking market in India, and more

time-read
3 分  |
January 19, 2025
The 2025 Slate
Business Today India

The 2025 Slate

The Indian film industry is hoping that 2025 will mark the return of big-budget blockbusters

time-read
3 分  |
January 19, 2025
TECH, SET, GO!
Business Today India

TECH, SET, GO!

With up to 30 tech start-ups looking to go public, the year promises to be a turning point for India's thriving start-up ecosystem

time-read
3 分  |
January 19, 2025